WND company achieves breakthrough in innovative nuclear medicine

WND-based Norroy Bioscience specializes in radiopharmaceuticals. [Photo/WeChat account: xinwu_wx]

A breakthrough has been made in nuclear medicine innovation by Xinwu-based Norroy Bioscience. The company's independently developed nuclear medicine for kidney cancer diagnosis, 68Ga-NYM005, has completed phase I/II clinical trials and is now entering the later stages of clinical development.

Founded in 2021, Norroy Bisoscience specializes in radiopharmaceuticals and automated medical equipment. The company collaborates with Jiangnan University, Peking Union Medical College Hospital, and leading experts in nuclear medicine to advance integrated cancer diagnosis and treatment, particularly for hard-to-treat cancers such as pancreatic cancer, kidney cancer, and neuroendocrine tumors.

Nuclear medicine, also known as radiopharmaceuticals, utilizes radiation from radioactive isotopes for disease diagnosis and treatment. With vast market potential, industry leaders such as Novartis, Bayer, and AstraZeneca are actively expanding their nuclear medicine pipelines.

Teddy Clinical Research Laboratory in WND. [Photo/WeChat account: xinwu_wx]

Wuxi Teddy Medical Testing in Xinwu district is also making strides in the nuclear medicine field. The company is establishing a radiopharmaceutical testing platform that will support pharmacokinetics, metabolic stability, excretion studies, and material balance and metabolite identification for innovative radiopharmaceuticals.

In recent years, Xinwu district, also known as Wuxi National Hi-Tech District, has been committed to fostering high-quality growth in the nuclear medicine and biopharmaceutical industries. The district aims to build an internationally competitive industrial cluster by supporting measures such as research and development funding of up to 20 million yuan ($2.77 million) for innovative drug companies, along with incentives of up to 10 million yuan for enterprises expanding into capital markets and moving up the value chain.